Dendritic cells and interleukin 12 as adjuvants for tumor-specific vaccines.
Grohmann
U
U
Department of Experimental Medicine, University of Perugia, Italy.
Bianchi
R
R
Belladonna
M L
ML
Silla
S
S
Surace
D
D
Fioretti
M C
MC
Puccetti
P
P
D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000818:Animals; D000951:Antigens, Neoplasm; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D019496:Cancer Vaccines / Q000008:administration & dosage*; D002454:Cell Differentiation; D003713:Dendritic Cells / Q000276:immunology*; D015395:Histocompatibility Antigens Class I / Q000378:metabolism; D007167:Immunotherapy / Q000379:methods; D018664:Interleukin-12 / Q000008:administration & dosage*; D051379:Mice; D009374:Neoplasms, Experimental / Q000276:immunology / Q000628:therapy; D018417:Th1 Cells / Q000166:cytology / Q000276:immunology
D000276:Adjuvants, Immunologic; D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; D015395:Histocompatibility Antigens Class I; D018664:Interleukin-12